首页> 外文期刊>World Journal of Gastroenterology >Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy.
【24h】

Small bowel non-Hodgkin's lymphoma remaining in complete remission by surgical resection and adjuvant rituximab therapy.

机译:小肠非霍奇金淋巴瘤可通过手术切除和利妥昔单抗辅助疗法完全缓解。

获取原文
获取原文并翻译 | 示例
       

摘要

A 44-year-old man was referred to our hospital with intermittent abdominal pain. Because distention of fluid- and gas-filled loops of small intestine was proved by X-ray, the patient was diagnosed as having small bowel obstruction. A laparotomy revealed a segmental stenosis in the jejunum, which showed diffuse thickening of the intestinal wall. Some mesenteric lymph nodes were swollen. Pathological examination was defined. We diagnosed diffuse large B-cell lymphoma based on the pathological findings of diffuse transmural infiltration of large lymphoid cells and flow-cytometric analyses. Rituximab was administered as adjuvant therapy at weekly doses of 375 mg/m(2). Four cycles were performed every 6 mo and he remained CR. Rituximab may be effective as adjuvant therapy.
机译:一名44岁的男子因间歇性腹痛转诊到我们医院。由于X射线证实小肠充满液体和充满气体的gas肿胀,因此该患者被诊断为肠梗阻小。开腹手术显示空肠段狭窄,肠壁弥漫性增厚。一些肠系膜淋巴结肿大。定义了病理检查。我们根据大淋巴样细胞的弥漫性透壁浸润的病理学发现和流式细胞术分析诊断为弥漫性大B细胞淋巴瘤。利妥昔单抗作为辅助治疗,每周一次剂量为375 mg / m(2)。每6个月执行4个周期,他保持CR。利妥昔单抗可能作为辅助疗法有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号